



Data Featured at AAD 2026

**American Academy of
Dermatology**

Denver, Colorado
March 27-31, 2026

J&J Sponsored Studies

Abstract Number	Title	Presentation time (MST)
<i>Icotrokinra studies</i>		
<i>ICONIC-ADVANCE 1&2 studies</i>		
ePoster with Oral Presentation		
73228	Durability of Response With Icotrokinra, a Targeted Oral Peptide, in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials	Saturday, March 28 9:30-9:35am Lobby C, Poster Center 1
ePoster Presentation		
73485	Robust Icotrokinra Systemic and Skin Pharmacodynamic Effects Versus Deucravacitinib in Patients With Moderate-to-Severe Plaque Psoriasis: Results From Phase 3, ICONIC-ADVANCE-1 Study	N/A
<i>ICONIC-LEAD studies</i>		
ePoster with Oral Presentation		
73600	Durability of Icotrokinra (Targeted Oral Peptide) Effects in Adolescents With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the ICONIC-LEAD Study	Saturday, March 28 10:25-10:30am Lobby C, Poster Center 1
73603	Early and Durable Improvements in Patient-Reported Outcomes With the Targeted Oral Peptide Icotrokinra in Adolescents With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the ICONIC-LEAD Study	Saturday, March 28 10:30-10:35 Lobby C, Poster Center 1
<i>ICONIC-LEAD, ADVANCE 1&2 studies</i>		
ePoster with Oral Presentation		
72984	Consistency of Skin Clearance With the Targeted Oral Peptide Icotrokinra: Results From a Large Pooled Cohort of Phase 3 Study Participants With Moderate-to-Severe Plaque Psoriasis	Friday, March 28 3:20-3:25pm Lobby C, Poster Center 1
ePoster with Oral Presentation		
73233	Treatment of Plaque Psoriasis Involving High-Impact Sites With Icotrokinra, a Targeted Oral Peptide: Pooled Analyses of 4 Phase 3 Placebo-Controlled Trials	Saturday, March 28 9:35-9:40am Lobby C, Poster Center 1
<i>ICONIC-LEAD, TOTAL, ADVANCE 1&2 studies</i>		
ePoster		
73451	Exposure - Response (ER) Relationships of Icotrokinra in Participants With Plaque Psoriasis: Phase 3 Results	N/A

Guselkumab studies		
<i>APEX study</i>		
ePoster with oral presentation		
72888	APEX: Guselkumab Response and Inhibition of Structural Damage Progression in Active Psoriatic Arthritis by Participant Baseline Characteristics	Saturday, March 28 8:55-9:00am Lobby C, Poster Center 1

VISIBLE study		
ePoster with oral presentation		
75354	VISIBLE Cohort A: Guselkumab Skin Clearance and Patient-Reported Outcomes Across Skin and Joint Symptoms Through Week 100 in Participants With Moderate-to-Severe Plaque Psoriasis Across All Skin Tones	Friday, March 27 10:45-10:50am Lobby C, Poster Center 2

VOYAGE 1&2 studies		
ePoster		
73456	Patient-Level Persistence of On-Treatment Remission With Guselkumab: Pooled Results From VOYAGE 1 and VOYAGE 2 Participants With Moderate-to-Severe Plaque Psoriasis	N/A

GUIDE study		
ePoster		
73753	Guselkumab Re-Treatment After Withdrawal: Rapid Regain of Disease Control in Super-Responders With Moderate-to-Severe Plaque Psoriasis - Final Week 220 Phase 3b GUIDE Findings	N/A

G-REAL studies		
ePoster		
72716	Guselkumab Shows Better Long-Term Effectiveness and Drug Survival Compared to Secukinumab Through 84 Weeks in Patients With Moderate-to-Severe Plaque Psoriasis – Results From the German Non-Interventional G-REAL Study	N/A
72640	Enhanced Effectiveness of Guselkumab as First-Line Biologic Therapy in Psoriasis: Real-World Results Over 84 Weeks From the G-REAL Study	N/A

SWEGUS study		
ePoster		
77617	Retrospective Non-Interventional Chart Review of Guselkumab and Risankizumab in Swedish Patients With Plaque Psoriasis	N/A

RWE study		
ePoster		
77535	Clinical Outcomes of Guselkumab in Biologic-Naïve Psoriasis Patients With Short and Long Disease Durations: A Real-World Study in Taiwan	N/A

<i>SPECTRUM study</i>		
ePoster		
72091	SPECTREM: Guselkumab Skin Clearance and Patient-Reported Outcome Results Across Skin and Joint Symptoms Through Week 48 in Low Body Surface Area, Moderate Plaque Psoriasis With at Least One Moderate High-Impact Site Involved	N/A

<i>ENCOMPASS study</i>		
ePoster Presentation		
74554	Adolescents With Psoriasis in the United States: Current Treatment Landscape and Unmet Needs	N/A